The role of proteoglycan and glycosaminoglycan in pulmonary diseases.

The role of proteoglycan and glycosaminoglycan in pulmonary diseases. - The role of proteoglycan and glycosaminoglycan in pulmonary diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005480

Enrollment

500

Registered

2011-04-21

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed as having pulmonary diseases such as interstitial pneumonia, sarcoidosis, acute pneumonia, chronic obstructive pulmonary disease (COPD), eosinophilic pneumonia and lung cancer in the Department of Pulmonary Medicine, Fukushima Medical University Hospital and normal volunteers. They received serum and/or BAL fluid sampling, and agreed to be involved in this clinical study.

Exclusion criteria

Exclusion criteria: Patients with pulmonary diseases without serum and/or BAL fluid sampling.

Design outcomes

Primary

Measure	Time frame
The relationship between proteoglycan and glycosaminoglycan in serum and BAL fluid and severity and prognosis of pulmonary diseases.	—

Secondary

Measure	Time frame
The relationship between proteoglycan and glycosaminoglycan in serum and BAL fluid and clinical parameters of pulmonary diseases.	—

Countries

Japan

Contacts

Public ContactYoshinori Tanino

School of Medicine, Fukushima Medical University Department of Pulmonary Medicine

pulmo@fmu.ac.jp024-547-1360

Outcome results